Testosterone Undecanoate (Investigational): The Complete HRT Guide

Quick Reference Card

Overview / What Is Testosterone Undecanoate?

The Basics

Testosterone undecanoate is an oral form of testosterone that is currently being studied for use in menopausal women who experience persistent low sexual desire. It is important to understand from the outset that this medication is not approved for women anywhere in the world. It is approved for men in several countries as a treatment for low testosterone, and researchers are now investigating whether a much lower dose could safely help women with a specific condition called hypoactive sexual desire disorder (HSDD).

Most people think of testosterone as a "male hormone," but women's bodies produce it too, just in much smaller amounts. Testosterone plays important roles in sexual desire, energy, and general wellbeing. During and after menopause, testosterone levels gradually decline, and some women develop a distressing loss of sexual desire that does not respond to estrogen-based hormone therapy alone. For these women, testosterone supplementation has shown benefit in clinical trials, primarily using patches and creams applied to the skin.

The challenge is that there is no approved testosterone product specifically designed for women in the United States or most other countries. Women who receive testosterone therapy today typically use male products at a fraction of the intended dose, or compounded formulations. This is where testosterone undecanoate enters the picture. Its unique formulation allows it to be absorbed through the intestinal lymphatic system rather than passing through the liver like most oral medications, which may offer advantages in terms of safety. A Phase 2 clinical trial is currently evaluating a 50 mg daily dose (roughly one-eighth of the male starting dose) in menopausal women with HSDD.

This guide summarizes what is currently known about testosterone undecanoate in the context of women's health. Because the research is early-stage, much of this guide draws on broader evidence about testosterone therapy for women and the established pharmacology of oral TU. Readers should understand that clinical practice recommendations cannot be made for an investigational agent, and all treatment decisions should be made with a qualified healthcare provider.

The Science

Testosterone undecanoate (TU) is a long-chain fatty acid ester prodrug of testosterone (17-beta-hydroxyandrost-4-en-3-one undecanoate). The undecanoic acid ester renders the molecule sufficiently lipophilic to be preferentially absorbed via intestinal lymphatics rather than the portal venous system, thereby partially bypassing first-pass hepatic metabolism that renders unesterified oral testosterone virtually inactive [1][2].

The compound was first developed in the 1970s and has been available internationally for male hypogonadism (as Andriol/Andriol Testocaps) for over three decades. In the United States, three oral TU products have received FDA approval for men since 2019: JATENZO (2019), TLANDO (2022), and KYZATREX (2022), all using self-emulsifying drug delivery systems (SEDDS) to enhance lymphatic absorption [3].

Interest in oral TU for women stems from an unmet clinical need. Despite the 2019 Global Consensus Position Statement from 11 international medical societies endorsing testosterone therapy for postmenopausal HSDD, no female-specific testosterone product has received regulatory approval in the US, Europe, or most other jurisdictions [4]. The only exception is Australia, where AndroFeme 1% testosterone cream was approved in 2022. Women worldwide are treated with off-label male formulations at dose-adjusted levels or compounded preparations, a situation the consensus panel described as an "unmet need" requiring urgent attention [4].

The sole randomized controlled trial of oral TU specifically in women (Tungmunsakulchai et al., 2015) demonstrated significant improvement in sexual function scores with 40 mg twice weekly over 8 weeks, with a safety profile comparable to placebo at that dose and duration [5]. A Phase 2 open-label trial (NCT06082817) is evaluating the modern SEDDS formulation (Kyzatrex) at 50 mg daily in 30 menopausal women with HSDD and low testosterone [6].

Medical / Chemical Identity

Brand Names (Male Formulations):

Key Structural Notes:

• Ester prodrug: TU itself is pharmacologically inactive; activity depends on hydrolysis to testosterone
• Long-chain undecanoic acid ester confers lipophilicity sufficient for lymphatic absorption
• Distinct from methyltestosterone (17-alpha-methylated), which causes hepatotoxicity
• No 17-alpha alkylation, which eliminates the hepatotoxicity risk associated with older oral androgens

Mechanism of Action

The Basics

To understand how testosterone undecanoate works, it helps to know two things: what testosterone does in a woman's body, and how this particular formulation gets it there.

Testosterone is an androgen, a class of hormones that both men and women produce. In women, testosterone is made primarily by the ovaries and the adrenal glands. It acts on androgen receptors found throughout the body, including in the brain (where it influences sexual desire and mood), in muscles and bones (where it supports strength and density), and in the skin and hair follicles (where it can affect hair growth patterns and oil production).

During menopause, testosterone production declines gradually. This decline is less abrupt than the drop in estrogen, but by midlife, women's testosterone levels are roughly 50% lower than in their twenties. For some women, this decline contributes to a marked loss of sexual desire that causes significant personal distress, a condition formally called hypoactive sexual desire disorder (HSDD).

Testosterone undecanoate is a specially designed form of testosterone attached to a fatty acid chain. When you swallow the capsule with food, the fatty acid attachment causes the medication to be absorbed through your lymphatic system (the network of vessels that normally transports dietary fats) rather than going directly to the liver. This matters because the liver very efficiently breaks down unmodified testosterone, which is why simply taking a testosterone pill does not work. By using the lymphatic route, testosterone undecanoate gets a portion of its payload into the bloodstream intact. Once there, enzymes in the blood and tissues clip off the fatty acid chain, releasing active testosterone.

The food requirement is important. Testosterone undecanoate must be taken with a meal containing fat to trigger the lymphatic absorption pathway. Taking it on an empty stomach dramatically reduces its effectiveness.

The Science

Testosterone undecanoate exploits the intestinal lymphatic transport pathway for drug absorption. The undecanoic acid (C11) ester chain confers sufficient lipophilicity (log P approximately 7.2) to promote incorporation into intestinal chylomicrons during postprandial lipid absorption [1][2].

Following oral administration with a fat-containing meal, TU is absorbed by intestinal enterocytes and incorporated into chylomicrons in the Golgi apparatus, which are then secreted into mesenteric lymph vessels rather than the portal venous system. This lymphatic route delivers TU to the systemic circulation via the thoracic duct, bypassing first-pass hepatic metabolism [2].

Definitive studies using stable isotope methodology in lymph duct-cannulated models demonstrated that 91.5-99.7% of systemically available TU ester is delivered via lymphatic transport, and 83.6-84.1% of systemically available testosterone derives from hydrolysis of lymphatically transported TU [2]. The absolute oral bioavailability of TU is low (approximately 3%) for the parent ester, but the clinically relevant endpoint is the resulting serum testosterone elevation, which is sufficient at appropriate doses.

Once in systemic circulation, TU undergoes hydrolysis by nonspecific esterases in plasma and tissues to release testosterone and undecanoic acid. The undecanoic acid moiety is metabolized via beta-oxidation (a normal fatty acid degradation pathway). Released testosterone then acts through the androgen receptor (AR), a nuclear hormone receptor expressed in reproductive tissues, brain, bone, muscle, adipose tissue, and cardiovascular endothelium [7].

Testosterone may also be converted to two important metabolites: 5-alpha-dihydrotestosterone (DHT) via 5-alpha-reductase (a more potent AR agonist), and estradiol via aromatase (CYP19A1) [7]. In women receiving physiological testosterone supplementation, the conversion to estradiol is quantitatively small and does not significantly alter circulating estradiol levels [4].

Modern SEDDS (self-emulsifying drug delivery system) formulations such as Kyzatrex incorporate surfactants and co-solvents that promote spontaneous emulsification in the GI tract, enhancing chylomicron incorporation and potentially improving the consistency of lymphatic absorption compared to older oil-based formulations [3].

Pathway & System Visualization

Pharmacokinetics / Hormone Physiology

The Basics

Understanding how testosterone undecanoate moves through your body helps explain both its potential benefits and its limitations.

When you take a testosterone undecanoate capsule with a meal, the medication hitches a ride with the fats you have eaten. Your intestinal cells package dietary fats into tiny particles called chylomicrons, and the testosterone undecanoate gets incorporated into these particles. Instead of going to the liver (where testosterone would be broken down), the chylomicrons travel through your lymphatic system, eventually emptying into your bloodstream near the heart.

Once in the blood, the fatty acid chain is clipped off by enzymes, releasing active testosterone. This process is not perfectly efficient; only a small percentage of the dose actually makes it through to become active testosterone. But at appropriate doses, this is enough to raise testosterone levels into the normal premenopausal range for women.

In the one dedicated pharmacokinetic study in women (using Andriol Testocaps at 20, 40, and 80 mg doses), testosterone levels rose in a dose-proportional manner, meaning that doubling the dose roughly doubled the testosterone level [8]. The 40 mg dose produced testosterone elevations within a range that would be considered physiological for premenopausal women.

The meal dependency is one of the practical realities of this medication. A fat-containing meal is essential. Taking the capsule on an empty stomach or with a very low-fat meal significantly reduces absorption.

The Science

Absorption: Oral TU bioavailability is highly food-dependent. Postprandial administration with a fat-containing meal is required for adequate lymphatic absorption. The absolute bioavailability of the TU ester is approximately 3% [2], but this is sufficient to produce clinically meaningful testosterone elevations due to the high potency of testosterone at physiological female concentrations (typically 15-70 ng/dL total testosterone).

In healthy postmenopausal women administered Andriol Testocaps [8]:

The dose-proportional testosterone response with sub-proportional DHT at higher doses suggests saturation of 5-alpha-reductase conversion, which may be clinically favorable (limiting DHT-mediated androgenic side effects) [8].

Distribution: Testosterone in women is approximately 66% bound to sex hormone-binding globulin (SHBG), 33% to albumin, and 1-2% circulates free [7]. SHBG binding is important because it affects free testosterone availability. Estrogen therapy (often concurrent in HRT users) increases SHBG production, which can reduce free testosterone. The Tungmunsakulchai RCT observed a decrease in SHBG in the testosterone group (from 81.09 to 65.84 nmol/L), consistent with testosterone's known SHBG-lowering effect [5].

Metabolism: TU is hydrolyzed by nonspecific esterases to testosterone and undecanoic acid. Testosterone is subsequently metabolized via:

• 5-alpha-reduction to DHT (5-alpha-reductase types 1 and 2)
• Aromatization to estradiol (CYP19A1)
• Hepatic conjugation (glucuronidation, sulfation) for renal excretion
• CYP3A4-mediated oxidation (minor pathway)

Elimination: Testosterone has a plasma half-life of approximately 10-100 minutes. The ester (TU) itself has a longer apparent half-life due to slow release from lymphatic depot and ongoing hydrolysis [3].

Understanding how your body absorbs and metabolizes hormones is one thing. Tracking your actual protocol — doses, timing, and route — gives you the data to have more productive conversations with your prescriber. Doserly lets you log every dose with route-specific detail, building a clear record of your hormone protocol over time.

Whether you're on patches, gels, oral tablets, or a combination, the app tracks your schedule and flags when doses are due. When your provider asks how your protocol has been going, you'll have a precise answer instead of a best guess.

Research & Clinical Evidence

The Basics

The research on testosterone undecanoate specifically for women is at an early stage. One small randomized controlled trial and one ongoing clinical trial form the core of the evidence base. However, the broader evidence for testosterone therapy in women with HSDD is more robust, and it provides important context.

The core finding across all testosterone studies in women: adding testosterone (primarily as patches or creams) to estrogen-based HRT can modestly but meaningfully improve sexual desire and satisfaction in postmenopausal women with HSDD. A comprehensive 2019 meta-analysis pooling data from multiple randomized trials found that testosterone therapy increased the number of satisfying sexual events by approximately one additional event per month compared to placebo and improved sexual desire, arousal, and orgasm [9].

What the oral TU study found: The one randomized trial specifically using oral testosterone undecanoate in women (Tungmunsakulchai et al., 2015) enrolled 70 postmenopausal women with sexual dysfunction. The testosterone group (40 mg twice weekly with daily estrogen) showed significantly better overall sexual function scores and arousal scores compared to the estrogen-only group after 8 weeks. No significant differences in side effects were observed [5].

What we do not yet know: Whether the modern oral TU formulation (Kyzatrex) at 50 mg daily produces physiological testosterone levels in women safely, whether the lipid effects that concern clinicians about oral testosterone are avoided with lymphatic-absorption formulations, and whether the benefits seen in the small Thai trial can be replicated in a larger, more diverse population.

The Science

Tungmunsakulchai et al. (2015) — The Only Oral TU RCT in Women [5]

This double-blind, placebo-controlled trial randomized 70 postmenopausal women to oral TU 40 mg twice weekly plus daily estradiol valerate 1 mg, or placebo plus estradiol valerate 1 mg, for 8 weeks. The primary endpoint was the Female Sexual Function Index (FSFI) total score.

Results: Post-treatment FSFI was 28.6 +/- 3.6 (TU) vs 25.3 +/- 6.7 (placebo), p = 0.04. The arousal subdomain showed the most robust improvement (p = 0.02). Safety markers (hematocrit, liver enzymes, lipid panel) showed no significant changes. Free androgen index increased significantly in the TU group (1.42 vs placebo 0.51, p < 0.05).

Limitations: Small sample (n=70), short duration (8 weeks), single center, no endometrial assessment, older oil-based TU formulation.

Islam et al. (2019) — Systematic Review and Meta-Analysis of Testosterone Therapy for Women [9]

The most comprehensive meta-analysis to date, published in the Lancet Diabetes and Endocrinology, pooled data from 36 RCTs (8,480 participants). Key findings for transdermal testosterone (the most-studied route):

• Satisfying sexual events: significant increase (mean difference approximately 0.85 events/4 weeks)
• Sexual desire: significant improvement across measures
• Arousal, orgasm, responsiveness, self-image, and reduced sexual distress: all significantly improved
• No significant increases in serious adverse events
• Mild acne and hair growth were the most common side effects

Kyzatrex Phase 2 Trial (NCT06082817) — Ongoing [6]

Open-label, single-arm, single-center study of 50 mg daily oral TU (SEDDS formulation) in 30 menopausal women with HSDD and low testosterone (< 30 ng/dL). Primary endpoints: safety and pharmacokinetics. Secondary endpoint: HSDD efficacy. Results not yet available.

Houwing et al. (2003) — PK Study in Women [8]

Dose-proportionality study in 45 healthy postmenopausal women at 20, 40, and 80 mg oral TU (Andriol Testocaps). Demonstrated dose-proportional testosterone response with evidence of 5-alpha-reductase saturation at higher doses (lower-than-expected DHT).

Evidence & Effectiveness Matrix

The following matrix uses the 20 HRT symptom/outcome categories. Because testosterone undecanoate is investigational for women, most categories have limited or no specific data. Evidence scores reflect the broader testosterone-for-women evidence base where applicable, with the specific oral TU evidence noted.

Categories not scored (insufficient data): Vasomotor Symptoms, Sleep Quality, Anxiety & Stress Response, Genitourinary Health (GSM), Metabolic Health, Joint & Musculoskeletal Health, Energy & Fatigue, Headache & Migraine, Endometrial Safety, Menstrual & Reproductive, Other Physical Symptoms.

Benefits & Therapeutic Effects

The Basics

The potential benefit of testosterone undecanoate for women centers on one specific indication: improving sexual desire in postmenopausal women with HSDD. The broader evidence for testosterone therapy in women shows meaningful improvement in sexual desire, arousal, orgasm, and satisfaction, along with a reduction in sexual distress.

If you are a postmenopausal woman who has experienced a significant decline in sexual desire that causes you personal distress, and you have already tried optimizing estrogen-based HRT without adequate improvement, testosterone supplementation may help. The evidence suggests that women with HSDD who receive testosterone therapy experience roughly one additional satisfying sexual event per month compared to those who receive placebo, alongside improvements in desire and arousal that, while statistically modest, can be personally meaningful [4][9].

It is worth noting what testosterone supplementation has NOT been shown to improve in women: general wellbeing, energy, cognitive function, mood, bone density, or body composition. While some women report improvements in these areas, the clinical trial evidence does not support testosterone for these indications. The Global Consensus Position Statement endorsed by 11 international medical societies is clear on this point: HSDD is the sole evidence-based indication [4].

The potential advantage of an oral formulation like testosterone undecanoate, if proven safe and effective in women, would be convenience. Currently available transdermal testosterone requires daily application of gels or creams, careful attention to skin-to-skin transfer risks, and dose adjustment using products not designed for female physiology. An oral capsule taken with a meal would simplify the treatment experience.

The Science

Sexual Function (HSDD)

The meta-analysis by Islam et al. (2019) is the definitive evidence synthesis. Across 36 RCTs including 8,480 participants, testosterone therapy (predominantly transdermal) demonstrated statistically significant improvements in [9]:

• Satisfying sexual events (SMD 0.36, 95% CI 0.22-0.50)
• Sexual desire (SMD 0.36, 95% CI 0.22-0.49)
• Orgasm (SMD 0.27, 95% CI 0.14-0.40)
• Arousal and responsiveness
• Reduction in personal distress related to sexual function

For oral TU specifically, the Tungmunsakulchai RCT showed improvement in total FSFI score (28.6 vs 25.3, p = 0.04) and arousal domain (4.17 vs 3.45, p = 0.02) at 8 weeks. While this single small trial cannot establish efficacy, it is directionally consistent with the broader testosterone evidence base [5].

Other Endpoints (Insufficient Evidence)

Per the 2019 Global Consensus Statement [4]:

• Wellbeing: No effect (Level I, Grade A)
• Mood/Depression: No effect (Level I, Grade B)
• Cognition: Insufficient evidence
• Bone mineral density: No effect at 12 months (Level I, Grade A)
• Body composition: No significant effect on lean mass, fat, or strength (Level I, Grade A)

Risks, Side Effects & Safety

The Basics

Understanding the safety profile of testosterone undecanoate requires distinguishing between what we know about testosterone therapy in women generally, what we know about oral testosterone specifically, and what remains unknown about the newer oral TU formulations.

Common side effects of testosterone therapy in women (at physiological doses) include mild acne and slight increases in facial or body hair growth. These are generally manageable and often resolve with dose adjustment. At physiological doses, testosterone therapy has NOT been associated with voice deepening, significant hair loss, or clitoromegaly [4].

The oral route concern is the most important safety consideration for testosterone undecanoate in women. The 2019 Global Consensus Statement specifically recommends against oral testosterone for women because oral testosterone is associated with adverse lipid profile changes, particularly reductions in HDL ("good" cholesterol) and increases in LDL ("bad" cholesterol) [4]. This recommendation was based primarily on older oral testosterone formulations and methyltestosterone, which undergo extensive first-pass hepatic metabolism.

The key question for newer oral TU formulations like Kyzatrex is whether lymphatic absorption (which partially bypasses the liver) results in a more favorable lipid profile. This is precisely what the ongoing Phase 2 trial aims to evaluate, but results are not yet available.

What the small existing trial showed: In the Tungmunsakulchai RCT (40 mg twice weekly for 8 weeks), there were no significant changes in total cholesterol, HDL, LDL, or triglycerides in the testosterone group compared to placebo [5]. However, 8 weeks is too short and 70 patients too few to draw definitive safety conclusions.

Cardiovascular risk: Testosterone therapy in women has not been associated with increases in blood pressure, blood glucose, or HbA1c. There is a non-significant trend for increased deep vein thrombosis risk, though the role of concurrent estrogen therapy in this finding cannot be excluded [4].

Breast cancer: Short-term transdermal testosterone does not increase mammographic breast density and does not appear to increase breast cancer risk. Long-term data are lacking, and women with hormone-sensitive breast cancer were excluded from clinical trials [4].

The Science

Lipid Effects (Route-Dependent)

The consensus statement's recommendation against oral testosterone is based on Level I, Grade A evidence showing adverse lipid profiles with oral testosterone [4]. However, this evidence primarily derives from studies of:

• Methyltestosterone (17-alpha alkylated; completely different metabolic profile from TU)
• Older oral TU formulations without optimized lymphatic absorption

Androgenic Side Effects at Physiological Doses [4]

In the Tungmunsakulchai RCT: acne 17.6% (TU) vs 14.2% (placebo), hirsutism 8.8% vs 8.5%; neither statistically significant [5].

Cardiovascular Considerations [4]

• Blood pressure: No increase with testosterone therapy
• Blood glucose / HbA1c: No increase
• DVT risk: Non-significant trend for increase; concurrent estrogen confounds
• Myocardial infarction / death: Insufficient data to assess

Breast Safety [4]

• Mammographic density: Not increased by testosterone (Level I, Grade A)
• Short-term breast cancer risk: No apparent increase with transdermal testosterone (Level I, Grade A)
• Long-term risk: Insufficient data (safety data available only to 24 months)
• Women with hormone-sensitive breast cancer: excluded from all trials; caution recommended

Hepatic Safety

Testosterone undecanoate does not have the 17-alpha alkylation that caused hepatotoxicity with methyltestosterone and fluoxymesterone. Newer oral TU formulations have not shown clinically significant hepatotoxicity in male clinical trials, though some transient liver enzyme elevations have been reported at male doses (200-800 mg/day) [3]. At the much lower female investigational doses (40-50 mg), hepatic safety concerns are theoretically minimal, but long-term data in women do not exist.

Contraindications (General for Testosterone in Women)

• Active or history of breast cancer
• Active cardiovascular disease (until further safety data available)
• Pregnancy or planned pregnancy
• Undiagnosed vaginal bleeding
• Active liver disease
• Polycythemia or hematocrit > 48%

Being informed about potential risks is important. Being able to track and document any side effects you actually experience is what turns awareness into safety. Doserly lets you log side effects as they happen, with timestamps and severity ratings, so nothing falls through the cracks between appointments.

If you're experiencing breakthrough bleeding, headaches, breast tenderness, or any other change, having a documented timeline helps your provider distinguish between expected adjustment effects and signals that warrant a protocol change. The app also checks for interactions between your HRT and any other medications or supplements you're taking.

Dosing & Treatment Protocols

The Basics

Because testosterone undecanoate is investigational for women, there are no established dosing guidelines for this specific medication. What exists are research protocols from clinical trials and dosing rationale based on the broader understanding of testosterone therapy for women.

The general principle for testosterone dosing in women is to use approximately 5-10% of the male dose, aiming to achieve testosterone levels within the normal premenopausal female range (typically 15-70 ng/dL total testosterone, though exact cutoffs vary by assay). This is a very different context from male testosterone replacement, where the goal is 300-1,000 ng/dL.

Doses studied in clinical trials:

• 40 mg oral TU twice weekly (Tungmunsakulchai RCT, older formulation)
• 50 mg oral TU daily (Kyzatrex Phase 2 trial, SEDDS formulation)
• 20, 40, and 80 mg single doses (Houwing PK study)

Important context: The 50 mg Kyzatrex dose was chosen because it is the lowest capsule strength currently manufactured and represents 12.5% of the male starting dose (400 mg/day). Clinical practice guidelines from ISSWSH suggest that the starting testosterone dose for women should be approximately 10% of a male-approved product dose [6].

Concurrent estrogen: The Tungmunsakulchai trial used concurrent daily estrogen. The Kyzatrex trial does not require concurrent estrogen. The Global Consensus Statement notes that most trials included women on concurrent estrogen therapy, and the data cannot be generalized to women not taking estrogen [4].

The Science

Dosing Rationale

The female testosterone dose is derived from the physiological sex difference in testosterone production. Premenopausal women produce approximately 0.1-0.4 mg of testosterone per day (compared to 3-10 mg/day in men), yielding circulating total testosterone of 15-70 ng/dL [7]. The therapeutic goal in HSDD is to restore testosterone to mid-normal premenopausal levels without exceeding the upper limit of the female range.

For oral TU, the low bioavailability (approximately 3% for the ester) means a much higher oral dose is needed relative to the target testosterone production rate. The 40-50 mg oral TU dose in women aims to deliver approximately 1.2-1.5 mg of bioavailable testosterone, achieving serum levels in the physiological female range [5][8].

Monitoring Protocol (Based on General Testosterone Guidelines) [4]

Treatment Duration

Per the Global Consensus Statement: if no benefit is experienced by 6 months, testosterone therapy should be discontinued [4]. Safety data for testosterone at physiological female doses are not available beyond 24 months.

Getting the dosing right often takes time and fine-tuning with your provider. Keeping an accurate record of what you're actually taking — doses, timing, and any adjustments — makes that process smoother. Doserly tracks your HRT doses alongside everything else in your health stack, so your full protocol is always in one place.

Never wonder whether you took your morning dose or when you last changed your patch. The app logs every dose with a timestamp and sends reminders when your next one is due, helping you maintain the consistency that makes hormone therapy most effective.

What to Expect (Timeline)

Because testosterone undecanoate is investigational for women, there is limited specific timeline data. The following is based on the broader testosterone-for-HSDD evidence and the 8-week Tungmunsakulchai trial:

• Days 1-7: No immediate changes expected. Testosterone levels begin to rise. Some women notice subtle mood or energy shifts, though this may reflect placebo expectation. Take capsule with a fat-containing meal consistently.
• Weeks 2-4: Early changes in sexual desire may begin. The Tungmunsakulchai trial measured outcomes at 8 weeks, suggesting effects develop over this timeframe. Mild acne or oily skin may appear.
• Months 1-3: Sexual desire, arousal, and satisfaction improvements typically become more apparent. The Phase 2 Kyzatrex trial evaluates outcomes at 3 months (12 weeks). Side effects (if any) are usually evident by this point.
• Months 3-6: If effective, benefits should be clearly established. Per consensus guidelines, if no benefit is experienced by 6 months, treatment should be discontinued. Provider should reassess testosterone levels and monitor for androgen excess.
• Ongoing: Long-term data for testosterone in women are limited to 24 months. Annual reassessment with healthcare provider is recommended. Continued monitoring of lipids, liver function, and signs of androgen excess.

Individual response varies. The meta-analysis data suggest that the treatment effect is moderate; testosterone supplementation helps some women significantly but is not a universal solution for low desire.

Timing Hypothesis & Window of Opportunity

The timing hypothesis, which suggests that HRT initiated within 10 years of menopause onset or before age 60 has a more favorable risk-benefit profile, applies primarily to estrogen-based therapies and their cardiovascular and neurological effects. Its applicability to testosterone therapy specifically is less clear.

What is known about testosterone timing:

• Testosterone levels decline gradually throughout the reproductive years, not abruptly at menopause [4]
• No cutoff testosterone level differentiates women with and without sexual dysfunction [4]
• The consensus statement does not specify an age or timing window for testosterone initiation
• Most RCT data come from postmenopausal women (natural or surgical) with a mean age range of 50-60 years

For women considering testosterone supplementation for HSDD, the timing considerations are more clinical than biological: ensuring that estrogen-based HRT has been optimized first, confirming that HSDD is not attributable to modifiable factors (relationship issues, medication side effects, psychological conditions), and conducting a comprehensive biopsychosocial assessment before initiating therapy [4][10].

Interactions & Compatibility

Drug-Drug Interactions:

• CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort): May reduce testosterone levels by increasing hepatic metabolism. Relevance to oral TU may be less than other oral testosterone because of lymphatic absorption, but interaction remains possible for the fraction undergoing hepatic metabolism.
• CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, grapefruit): May increase testosterone levels. Monitor for signs of androgen excess.
• Anticoagulants (warfarin): Testosterone may enhance anticoagulant effect; INR monitoring advised.
• Insulin and oral hypoglycemics: Testosterone may improve insulin sensitivity; glucose-lowering medication doses may need adjustment.
• Corticosteroids: Concurrent use may increase fluid retention risk.
• Estrogen therapy: Estrogen increases SHBG, which can bind and reduce free testosterone. Dose adjustment of testosterone may be needed in women on concurrent estrogen.

Supplement Interactions:

• DHEA (dehydroepiandrosterone): DHEA is a testosterone precursor; concurrent use may lead to supraphysiological androgen levels. Not recommended alongside testosterone therapy [4].
• Black cohosh: No known interaction with testosterone
• Saw palmetto: Theoretical 5-alpha-reductase inhibition could reduce DHT conversion; clinical significance uncertain

Lifestyle Factors:

• Smoking: Does not have the same estrogen-specific VTE amplification but general cardiovascular risk applies
• Alcohol: Modest interaction with liver metabolism; no specific testosterone-alcohol interaction established at female doses
• High-fat meals: Required for optimal oral TU absorption. Taking the capsule without adequate fat reduces effectiveness.

Cross-References:

• DHEA / Prasterone (Intrarosa) — related androgen therapy
• Testosterone Therapy for Women (Overview) — comprehensive testosterone overview
• Estradiol (Bioidentical) — commonly used concurrent estrogen

Decision-Making Framework

Deciding whether testosterone therapy is appropriate involves a careful, structured conversation with a healthcare provider who is knowledgeable about sexual health and menopause management. For testosterone undecanoate specifically, the conversation must include the additional consideration that this is an investigational use.

Who might be a candidate for testosterone therapy:

• Postmenopausal women (natural or surgical) with HSDD
• HSDD diagnosis confirmed through comprehensive biopsychosocial assessment
• Estrogen-based HRT has been optimized and found insufficient for sexual symptoms
• No contraindications to testosterone therapy
• Willingness to accept off-label treatment (for testosterone generally) or participation in a clinical trial (for oral TU specifically)

Who is likely NOT a candidate:

• Women whose low desire is primarily related to relationship issues, depression, medication side effects, or other modifiable factors
• Women seeking testosterone for energy, mood, cognition, or weight management (insufficient evidence)
• Women with active or history of hormone-sensitive breast cancer
• Women who are not comfortable with an investigational or off-label treatment approach

Questions to discuss with your provider:

• "Is my low desire likely related to hormonal changes, or could other factors be contributing?"
• "Have we fully optimized my estrogen-based HRT before considering testosterone?"
• "What formulation of testosterone would you recommend, and why?"
• "How will we monitor my testosterone levels and watch for side effects?"
• "What is the evidence for the specific formulation you are prescribing?"
• "How long should I try testosterone before we determine whether it is working?"

Finding a specialist:

• NAMS Certified Menopause Practitioners: menopause.org
• ISSWSH provider directory: isswsh.org
• Sexual medicine specialists
• Endocrinologists with experience in female androgen therapy

Administration & Practical Guide

Oral testosterone undecanoate capsules (investigational for women):

• Take with a meal: This is essential, not optional. The capsule must be taken with a fat-containing meal to activate the lymphatic absorption pathway. Taking it on an empty stomach dramatically reduces effectiveness.
• Timing: Take at approximately the same time each day for consistent levels. Morning or evening meal; choose whichever is most consistently a substantial meal.
• Swallow whole: Do not chew, crush, or open the capsule.
• Missed dose: If a dose is missed, take it with the next meal. Do not double up.
• Storage: Store at room temperature. Some formulations may have specific storage requirements.

Important notes:

• This information is educational and based on general oral TU administration guidance from male product labeling and clinical trial protocols
• Women should ONLY take testosterone undecanoate under the supervision of a healthcare provider, ideally as part of a clinical trial
• Self-prescribing male testosterone products at self-determined doses is strongly discouraged by all clinical practice guidelines

Monitoring & Lab Work

Pre-Treatment Baseline:

• Total testosterone (LC-MS/MS assay preferred for accuracy in female range)
• SHBG
• Lipid panel (total cholesterol, HDL, LDL, triglycerides)
• Liver function tests (ALT, AST)
• Complete blood count with hematocrit
• Mammogram (per age-appropriate guidelines)
• Clinical assessment for signs of androgen excess

Initial Follow-Up (3-6 weeks):

• Repeat total testosterone to confirm physiological female range (typically 15-70 ng/dL)
• If above physiological range, dose reduction or discontinuation indicated
• Symptom assessment

Ongoing Monitoring (every 6 months for first year, annually thereafter):

• Total testosterone
• Lipid panel
• Liver function tests
• Complete blood count
• Clinical assessment for acne, hirsutism, hair pattern changes
• Breast examination and mammography per guidelines
• Sexual function assessment (e.g., FSFI or clinical interview)

When to Discontinue:

• No benefit experienced after 6 months [4]
• Supraphysiological testosterone levels that cannot be corrected with dose adjustment
• Development of significant androgenic side effects
• Development of contraindication (breast cancer diagnosis, cardiovascular event)
• Patient preference

Assay Considerations:
The Global Consensus Statement emphasizes that direct immunoassays for testosterone are unreliable in the female range. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for measuring testosterone in women [4]. If LC-MS/MS is not available, direct assays can be used to exclude very high or very low levels, but precise quantification may be inaccurate.

Complementary Approaches & Lifestyle

For women with HSDD, a comprehensive approach that addresses multiple contributing factors alongside any pharmacological treatment is most effective.

Evidence-based complementary strategies:

• Cognitive behavioral therapy (CBT) and mindfulness-based therapies: Demonstrate efficacy for female sexual dysfunction, both alone and in combination with pharmacotherapy. The biopsychosocial model of HSDD treatment recommends psychological intervention as first-line or adjunctive therapy [10].
• Pelvic floor physiotherapy: Particularly relevant if sexual dysfunction includes pain or arousal difficulty. Can improve pelvic floor awareness and reduce dyspareunia.
• Exercise: Regular physical activity improves body image, cardiovascular fitness, and may modestly improve sexual function. Resistance training supports muscle mass and energy.
• Sleep optimization: Sleep disturbance (common in menopause) can significantly impair sexual desire and arousal. Addressing sleep through CBT-I or environmental modifications may improve sexual function indirectly.
• Stress management: Chronic stress and cortisol elevation can suppress gonadal function and reduce sexual desire. Mindfulness, yoga, and structured relaxation practices may help.
• Relationship counseling: HSDD is frequently intertwined with relationship dynamics. Couples therapy or sex therapy can address interpersonal factors that pharmacotherapy alone cannot.

Supplements with limited evidence:

• DHEA: Systemic DHEA has not shown significant improvement in sexual function for postmenopausal women with normal adrenal function [4]. Vaginal DHEA (prasterone) is approved for GSM but not for HSDD specifically.
• Maca root: Some preliminary evidence for mild libido improvement; insufficient for clinical recommendation.
• Fenugreek: Small studies suggest possible benefit; insufficient evidence.

Cross-links:

• DHEA / Prasterone
• Menopause Nutrition & Lifestyle

Stopping HRT / Discontinuation

When to consider stopping testosterone therapy:

• After 6 months if no benefit has been experienced [4]
• Annually as part of routine reassessment of ongoing need
• If significant side effects develop that are not manageable with dose adjustment
• If contraindications develop
• Patient preference

Discontinuation approach:

• Testosterone therapy can generally be stopped without a formal taper
• Unlike estrogen, testosterone cessation does not typically cause rebound vasomotor symptoms
• Sexual desire may return to pre-treatment levels; this does not indicate "withdrawal" but rather return to baseline hormonal status
• Some women choose to transition from oral TU to established transdermal testosterone if oral route is discontinued for safety reasons

What to monitor after stopping:

• Sexual function (expect possible return to pre-treatment levels)
• No specific laboratory monitoring needed for testosterone discontinuation alone
• If concurrent estrogen is also being changed, standard HRT monitoring applies

Special Populations & Situations

Surgically Menopausal Women

Bilateral oophorectomy causes an abrupt approximately 50% reduction in circulating testosterone. Women who develop HSDD after surgical menopause represent one of the most-studied populations for testosterone therapy. The evidence for testosterone supplementation is strongest in this group, though oral TU specifically has limited data [4].

Premature Ovarian Insufficiency (POI)

Women with POI (menopause before age 40) experience premature decline in all ovarian hormones, including testosterone. Expert opinion suggests management of HSDD should follow the same approach as for postmenopausal women, but data specific to this population are limited [10].

Premenopausal Women

There is insufficient evidence to recommend testosterone therapy in premenopausal women for HSDD or any other indication. The Global Consensus Statement specifically notes this evidence gap [4].

Women with Breast Cancer History

Women with prior hormone-sensitive breast cancer were excluded from all testosterone RCTs. The consensus statement recommends caution. Some observational data suggest testosterone alone (without estrogen) may not increase breast cancer risk, but prospective safety data are lacking.

Women on Concurrent Medications

Women taking medications that affect CYP3A4 or SHBG levels may have altered testosterone pharmacokinetics. Careful monitoring is particularly important for:

• Women on anticonvulsants (enzyme inducers)
• Women on antifungals or HIV protease inhibitors (enzyme inhibitors)
• Women on thyroid replacement (estrogen increases TBG, indirectly affecting free hormone levels)

Regulatory, Insurance & International

United States (FDA):

• No testosterone product is approved for women
• FDA declined to approve a transdermal testosterone patch for women in 2004 (IntrinsaR) citing lack of long-term safety data
• Testosterone for women is prescribed entirely off-label using male formulations at reduced doses or compounded preparations
• Kyzatrex (oral TU) is approved for men only; Phase 2 trial for women ongoing
• JATENZO and TLANDO are also approved only for men

Australia (TGA):

• AndroFeme 1% testosterone cream: the only approved female-specific testosterone product globally (approved 2022, Lawley Pharmaceuticals)
• Available by prescription for HSDD in postmenopausal women

United Kingdom (MHRA):

• No licensed testosterone product for women
• NICE NG23: "consider testosterone supplementation for menopausal women with low sexual desire if HRT alone is not effective"
• British Menopause Society supports off-label testosterone use for HSDD
• Male testosterone gels (Testogel, Tostran) used off-label at approximately 10% of male dose
• Significant variation in formulary positions across NHS regions ("postcode lottery")

European Union (EMA):

• No centrally authorized testosterone product for women
• Country-by-country availability of off-label male products varies

Canada (Health Canada):

• No approved female testosterone product
• Off-label use similar to US pattern

Insurance and Cost:

• Because no female product exists in most countries, cost and insurance coverage for off-label testosterone use varies widely
• Compounded testosterone preparations may not be covered by insurance
• Oral TU products (if ever approved for women) would likely face a new pricing and coverage landscape

Frequently Asked Questions

Q: Is testosterone undecanoate approved for women?
A: No. Testosterone undecanoate is approved for men with low testosterone in several countries (as Kyzatrex, JATENZO, TLANDO, or Andriol). It is currently in Phase 2 clinical trials for women with HSDD. No testosterone product of any type is approved for women in the US or most other countries, with the exception of Australia (AndroFeme cream).

Q: Can I use my partner's testosterone undecanoate capsules?
A: This is strongly discouraged. Male testosterone products contain doses far higher than what would be appropriate for women. Supraphysiological testosterone levels in women can cause irreversible side effects including voice deepening, clitoromegaly, and significant hair growth. All clinical practice guidelines recommend against using male testosterone formulations without healthcare provider supervision and dose adjustment.

Q: Why is there no approved testosterone product for women?
A: Regulatory agencies, particularly the FDA, have required long-term safety data that has not been generated through clinical trials. The absence of approved products is not because testosterone is considered unsafe for women, but because the pharmaceutical industry has not completed the large, long-duration trials that regulators require. The 2019 Global Consensus Statement called this an "unmet need" and urged industry and researchers to address it.

Q: How does oral testosterone undecanoate differ from testosterone gels or creams?
A: Oral TU is taken as a capsule with food and absorbed through the intestinal lymphatic system. Gels and creams are applied to the skin and absorbed transdermally. The transdermal route has more clinical evidence in women and does not affect lipid levels. Oral testosterone has historically been associated with adverse lipid changes, though newer formulations using lymphatic absorption may mitigate this concern. The potential advantage of oral TU is convenience.

Q: What is HSDD?
A: Hypoactive sexual desire disorder (HSDD) is a persistent or recurrent deficiency (or absence) of sexual fantasies and desire for sexual activity that causes marked personal distress or interpersonal difficulty. It is not simply a lower-than-desired libido; it requires both reduced desire and significant distress about that reduction. HSDD affects approximately 10% of women, with higher prevalence around menopause.

Q: If I have low testosterone levels, does that mean I have HSDD?
A: No. There is no testosterone blood level that can diagnose HSDD. Women with low testosterone levels may have perfectly normal sexual function, and women with normal testosterone levels may experience HSDD. The diagnosis is clinical, based on symptoms and distress, not on a blood test [4].

Q: Will testosterone help with my menopause fatigue and brain fog?
A: Current evidence does not support testosterone therapy for fatigue, cognitive function, mood, or general wellbeing in postmenopausal women. The only evidence-based indication is HSDD. While some women report subjective improvements in energy and mental clarity, clinical trials have not demonstrated these benefits [4].

Q: Is oral testosterone undecanoate safe for the liver?
A: Testosterone undecanoate is structurally different from the older oral androgens (methyltestosterone, fluoxymesterone) that caused liver toxicity. Those older drugs had a 17-alpha alkyl modification that is not present in TU. TU is absorbed primarily through the lymphatic system, bypassing much of the liver. In male clinical trials at much higher doses, TU has not shown significant hepatotoxicity, though some transient liver enzyme elevations have been reported. Data specific to women at lower doses are very limited.

Q: Can I take testosterone undecanoate without estrogen?
A: This is an open question. Most clinical trial data for testosterone in women come from studies where participants were also taking estrogen-based HRT. The Kyzatrex Phase 2 trial does not require concurrent estrogen. Whether oral TU alone is as effective as oral TU with concurrent estrogen for HSDD is unknown.

Q: How long would I need to take testosterone?
A: Guidelines recommend a trial of at least 3-6 months. If no benefit is experienced by 6 months, discontinuation is advised. For women who do benefit, the optimal duration is unknown. Safety data for testosterone in women are only available to 24 months. Annual reassessment with a healthcare provider is recommended.

Q: What happens if my testosterone levels get too high?
A: Supraphysiological testosterone levels in women can cause acne, excess hair growth, voice changes, hair thinning, and clitoral enlargement. Some of these effects (particularly voice changes) may be irreversible. This is why monitoring testosterone levels is essential, and why the consensus guidelines recommend targeting physiological premenopausal female levels only.

Myth vs. Fact

Myth: Testosterone is a male hormone and has no role in women's health.
Fact: Women produce testosterone naturally through the ovaries and adrenal glands. Premenopausal women have circulating testosterone levels of approximately 15-70 ng/dL. Testosterone plays roles in sexual desire, bone health, muscle function, and general wellbeing. Women actually produce more testosterone than estradiol for much of their reproductive years, though both are present in much lower concentrations than in men [7].

Myth: Taking testosterone will make me look masculine.
Fact: At physiological female doses (targeting normal premenopausal levels), testosterone therapy has not been associated with significant masculinizing effects. Clinical trial data from meta-analyses involving over 8,000 women show mild acne and slight increases in body/facial hair growth in some women, but no alopecia, voice changes, or clitoromegaly at recommended doses [4][9]. These side effects are dose-dependent and generally resolve with dose reduction. Masculinization risk comes from supraphysiological doses, which is why monitoring and appropriate dosing are essential.

Myth: An oral testosterone pill would be more dangerous than a patch or cream.
Fact: Historically, oral testosterone was associated with liver toxicity and adverse lipid changes, but this was primarily due to older formulations containing 17-alpha alkylated androgens (methyltestosterone). Testosterone undecanoate does not have this liver-toxic structural modification and is absorbed via the lymphatic system, partially bypassing the liver. Whether modern oral TU formulations have a comparable safety profile to transdermal testosterone in women remains to be established by ongoing clinical trials. The concern is not settled in either direction.

Myth: If my testosterone levels are low, I need testosterone supplementation.
Fact: There is no defined testosterone level that constitutes "deficiency" in women, and low testosterone levels do not predict sexual dysfunction. The 2019 Global Consensus Statement explicitly states that no cutoff blood level can be used to differentiate women with and without sexual dysfunction [4]. Testosterone therapy is indicated based on clinical symptoms (HSDD with associated distress) after comprehensive assessment, not based on a laboratory value.

Myth: Testosterone therapy increases breast cancer risk.
Fact: Available data from randomized controlled trials show that short-term transdermal testosterone therapy does not increase mammographic breast density and does not appear to increase breast cancer risk [4]. However, long-term data (beyond 24 months) are not available, and women with hormone-sensitive breast cancer were excluded from clinical trials. The relationship between testosterone and breast cancer is complex and not fully understood.

Myth: Compounded testosterone is safer than pharmaceutical products because it's "natural."
Fact: Compounded testosterone preparations are not subject to the same regulatory oversight, quality control testing, and batch consistency requirements as FDA-approved products. The Global Consensus Statement recommends against compounded testosterone unless an authorized equivalent is not available, and if compounded products are used, they should come from pharmacies compliant with Good Manufacturing Practice standards [4]. "Bioidentical" and "compounded" do not inherently mean safer or more effective.

Myth: Testosterone will solve all menopause-related sexual problems.
Fact: Sexual function in menopause is influenced by biological, psychological, and relational factors. Testosterone therapy addresses only the hormonal component. Clinical guidelines emphasize that a comprehensive biopsychosocial assessment is essential before considering testosterone, and that modifiable factors (relationship issues, depression, medication side effects, vaginal dryness treatable with local estrogen) should be addressed first [4][10]. Even in clinical trials, the treatment effect of testosterone is moderate, averaging approximately one additional satisfying sexual event per month compared to placebo.

Myth: Once you start testosterone, you can never stop.
Fact: Testosterone therapy can be discontinued at any time without a formal taper. Unlike estrogen cessation, stopping testosterone does not typically cause rebound vasomotor symptoms. Sexual desire may return to pre-treatment levels, but this represents a return to baseline, not a withdrawal effect. Guidelines recommend reassessing the need for ongoing therapy annually [4].

Sources & References

Clinical Guidelines

1. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. doi:10.1210/jc.2019-01603
2. Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021;18:849-867.
3. Wierman ME, Arlt W, Basson R, et al. Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(10):3489-3510. doi:10.1210/jc.2014-2260
4. Parish SJ, Kling JM. NAMS Practice Pearl: Testosterone Use for Hypoactive Sexual Desire Disorder in Postmenopausal Women. Menopause. 2023;30(7):781-783.

Clinical Trials

1. Tungmunsakulchai R, Chaikittisilpa S, Snabboon T, et al. Effectiveness of a low dose testosterone undecanoate to improve sexual function in postmenopausal women. BMC Womens Health. 2015;15:113. doi:10.1186/s12905-015-0270-6
2. ClinicalTrials.gov. An Open-Label Study of 50 mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women with Low Testosterone and HSDD. NCT06082817.

Systematic Reviews & Meta-Analyses

1. Islam RM, Bell RJ, Green S, Page M, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomized controlled trial data. Lancet Diabetes Endocrinol. 2019;7:754-766.
2. Achilli C, Pundir J, Ramanathan P, et al. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil Steril. 2017;107:475-482.
3. Somboonporn W, Bell JR, Davis RS, Seif MW, Bell R. Testosterone for peri and postmenopausal women. Cochrane Database Syst Rev. 2005;(4):CD004509.

Pharmacokinetic Studies

1. Houwing NS, Maris F, Schnabel PG, Bagchus WM. Pharmacokinetic study in women of three different doses of a new formulation of oral testosterone undecanoate, Andriol Testocaps. Pharmacotherapy. 2003;23(12):1257-1265.
2. Shackleford DM, Faassen WA, Houwing N, et al. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two Andriol formulations in conscious lymph duct-cannulated dogs. J Pharmacol Exp Ther. 2003;306(3):925-933.
3. Bagchus WM, Hust R, Maris F, Schnabel PG, Houwing NS. Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy. 2003;23:319-325.

Observational Studies & Reviews

1. Shifren JL. Testosterone for midlife women: the hormone of desire? Menopause. 2015;22(10):1147-1149.
2. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab. 2005;90(7):3847-3853.
3. Clayton AH, Goldstein I, Kim NN, et al. The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women. Mayo Clin Proc. 2018;93(4):467-487.

Government/Institutional Sources

1. VA Pharmacy Benefits Management. Transdermal Testosterone (Off-Label) for Hypoactive Sexual Desire Disorder (HSDD) in Postmenopausal Females: Summary Guidance. March 2025.
2. Bernstein JS, Dhingra OP. A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product (KYZATREX). Ther Adv Urol. 2024;16:17562872241241864. (Male data for KYZATREX formulation reference)

Related Guides & Cross-Links

Same Category (Androgens — Women's Context)

• DHEA / Prasterone (Intrarosa) — the other androgen option for women; vaginal DHEA approved for GSM

Related Treatment Options

• Testosterone Therapy for Women (Overview) — comprehensive guide to all testosterone formulations for women
• 17B-Estradiol (Bioidentical) — primary estrogen used in concurrent HRT
• Micronized Progesterone (Prometrium) — commonly paired with estradiol in HRT

Non-Hormonal Alternatives for Sexual Dysfunction

• Fezolinetant (Veozah) — non-hormonal for vasomotor symptoms (not for HSDD)
• Ospemifene (Osphena) — SERM for dyspareunia/GSM

Conditions & Stages

• Menopause — the clinical context for testosterone use
• Surgical Menopause — population with strongest testosterone evidence
• Premature Ovarian Insufficiency (POI) — early menopause with androgen considerations
• Sexual Health During Menopause — comprehensive sexual health guide

Educational

• Getting Started with HRT — foundational HRT guide
• HRT Monitoring & Lab Work Guide — monitoring protocols